GILEAD SCIENCES, INC. is 20.7x more valuable than ImmunityBio, Inc. by market capitalization ($151.05 B vs $7.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IBRX | GILD |
|---|---|---|
| Market cap | $7.31 B | $151.05 B |
| US-listed rank | #1120 | #99 |
| Revenue (latest FY) | $113.29M | $29.44B |
| Net income (latest FY) | -$351.50M | $8.51B |
| Net margin | -310.3% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 528 | 981 |
GILEAD SCIENCES, INC. is 20.7x more valuable than ImmunityBio, Inc. by market capitalization ($151.05 B vs $7.31 B).
In their latest fiscal years, ImmunityBio, Inc. reported $113.29M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: ImmunityBio, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.